KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors

Hong, D.; Fakih, M.; Strickler, J.; Desai, J.; Durm, G.; Shapiro, G.; Falchook, G.; Price, T.; Sacher, A.; Denlinger, C.; Bang, Y.; Dy, G.; Krauss, J.; Kuboki, Y.; Kuo, J.; Coveler, A.; Park, Keunchil; Won Kim, Tae; Barlesi, F.; Munster, P.; Ramalingam, S.; Burns, T.; Meric-Bernstam, F.; Henary, H.; Ngang, J.; Ngarmchamnanrith, G.; Kim, June; Houk, B.; Canon, J.; Lipford, J.; Friberg, G.; Lito, P.; Govindan, R.; T. Li, Bob

doi:10.1056/NEJMOA1917239

Public

KRASG12C Inhibition with Sotorasib in Advanced Solid Tumors

Shared by NobleBlocks on Sep 20, 2020 • 12:00 AM UTC

Authors:

D. Hong

M. Fakih

J. Strickler

Abstract

BACKGROUND No therapies for targeting KRAS mutations in cancer have been approved. The KRAS p.G12C mutation occurs in 13% of non–small-cell lung cancers (NSCLCs) and in 1 to 3% of colorectal cancers and other cancers. Sotorasib is a small molecule that selectively and irreversibly targets KRASG12C. ...

Subject

Medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!